Ruxolitinib for the treatment of myelofibrosis: its clinical potential

Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function. By inhibiting JAK1 and JAK2, ruxolitinib modu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostojic, Alen, Vrhovac, Radovan, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295626/
https://www.ncbi.nlm.nih.gov/pubmed/22399854
http://dx.doi.org/10.2147/TCRM.S23277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295626/
https://www.ncbi.nlm.nih.gov/pubmed/22399854
http://dx.doi.org/10.2147/TCRM.S23277

Ejemplares similares